Search
Emergent BioSolutions Inc
EBSAdd to Watchlist
8.280USD
+0.010+0.12%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
428.90MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.12%
5 Days
-2.93%
1 Month
-1.90%
6 Months
-33.81%
Year to Date
-33.01%
1 Year
+18.45%
Key Figures
8.390Open
8.530High
575.96KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
1.11%Turnover Ratio
8.280Prev. Close
8.115Low
2.22MTurnover
LossP/E Static
0.82P/B
0.00%Div Yield TTM
-0.63%ROA
14.06052wk High
1.04Volume Ratio
-190.60MNet Profit
51.80MShares
-0.1358EPS TTM
2.34Beta
-1.60%ROE
5.61552wk Low
5.01%Amplitude
53.88%Gross Margin
428.90MMarket Cap
-0.47Reward/Risk
3.99%Risk Rate
TradingKey Stock Score of Emergent BioSolutions Inc
Currency: USD Updated: 2026-07-02Key Insights
Emergent BioSolutions Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Emergent BioSolutions Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Emergent BioSolutions Inc Highlights
StrengthsRisks
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -60.97, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.30M shares, decreasing 7.38% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 233.33K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
12.000
Target Price
+44.93%
Upside Space
Emergent BioSolutions Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Emergent BioSolutions Inc Info
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Ticker SymbolEBS
CompanyEmergent BioSolutions Inc
CEOPapa (Joseph C)
Websitehttps://emergentbiosolutions.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Emergent BioSolutions Inc (EBS)?
The current price of Emergent BioSolutions Inc (EBS) is 8.28.
What is the symbol of Emergent BioSolutions Inc?
The ticker symbol of Emergent BioSolutions Inc is EBS.
What is the 52-week high of Emergent BioSolutions Inc?
The 52-week high of Emergent BioSolutions Inc is 14.06.
What is the 52-week low of Emergent BioSolutions Inc?
The 52-week low of Emergent BioSolutions Inc is 5.62.
What is the market capitalization of Emergent BioSolutions Inc?
The market capitalization of Emergent BioSolutions Inc is 428.90M.
Is Emergent BioSolutions Inc (EBS) currently rated as Buy, Hold, or Sell?
According to analysts, Emergent BioSolutions Inc (EBS) has an overall rating of Buy, with a price target of 12.00.
What is the Earnings Per Share (EPS TTM) of Emergent BioSolutions Inc (EBS)?
The Earnings Per Share (EPS TTM) of Emergent BioSolutions Inc (EBS) is 0.98.